SCENESSE (afamelanotide) — Topline data
Dec 2026
It is anticipated that the topline results of the CUV105 study will be ready for release in December 2026 ( see ASX announcement 28 July 2026 ).Source filing
CUVL biotech catalysts & pipeline
CLINUVEL PHARMACEUTICALS LTD · Data as of 2026-09-08